Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
No oncological concerns specific to the TREK-1 blockade mechanism have been identified
Some people need consistent dosing
Published pre-clinical studies have used FOXO4-DRI to demonstrate that selective elimination of senescent cells in aged mouse models can improve a range of tissue function parameters including fitness, fur density, renal function, and liver function establishing the broader research principle that senescent cell burden contributes meaningfully to ageing tissue dysfunction and that its targeted reduction produces measurable functional benefits in experimental models
Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms
Distinguishing purging from a true reaction tells you whether to wait it out or quit
US$ 27.91
US$ 25.17
US$ 28.17
